Hemispherx Biopharma, Inc. (Amex: HEB) plans to widen its ongoing clinical programs in CFS by accelerating collaborations with a consortium ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE